课题基金 / 基金详情

Pathophysiology of Biliary Cryptosporidiosis

Pathophysiology of Biliary Cryptosporidiosis
胆道隐孢子虫病的病理生理学
批准号:
7373535
负责人:
Nicholas F. LaRusso
金额:
$30.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-01 至 2011-11-30

项目摘要

项目成果

Nicholas F. LaRusso的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Our long-term OBJECTIVES remain to apply the fundamental concepts and broad technologies of cell and molecular biology to understand the role of cholangiocytes, the epithelial cells lining intrahepatic bile ducts, in health and disease. We continue to focus on the interactions between cholangiocytes and Cryptosporidium parvum (C. parvum), an emerging pathogen causing intestinal and biliary cryptosporidiosis. Recent evidence from our lab indicates that: (i) the cellular expression and regulation of key receptors [Toll-like receptors (TLRs)] and specific intracellular signaling pathways (NF-kB activation) are involved in cholangiocyte C. parvum recognition and strategic defense; and (ii) endogenous microRNA (miRNA)-mediated post- transcriptional gene regulation is involved in cholangiocyte defense responses to C. parvum infection. Thus, we will test the CENTRAL HYPOTHESIS that C. parvum-cholangiocyte interactions activate host-cell TLR/NF-kB signaling cascades initiating cholangiocyte defense responses including upregulation of both TLRs and anti-microbial peptides (defensins) through both transcriptional and post-transcriptional endogenous miRNA-mediated) regulatory pathways. In our three integrated SPECIFIC AIMS, we will test the hypotheses that: (i) cholangiocyte TLRs recognize C. parvum and modulate NF-kB activation resulting in upregulation of anti-microbial peptides (human beta-defensins [HBDs]) and TLRs through NF-kB mediated transcriptional regulation; (ii) miRNA-mediated post-transcriptional repression of TLR expression normally exists in cholangiocytes, is regulated by TLR/NF-kB signals, and is involved in C. parvum-induced upregulation of TLRs; and (iii) expression of TLRs and HBDs in cholangiocytes are required for eradication of C. parvum infection in the biliary tract in in vitro and in vivo experimental models. Innovative aspects of our program include: novel methodologies [small-interfering RNAs (siRNAs)], animal models (biliary cryptosporidiosis in wild type, TLR and MyD88 knock out mice), and new concepts (miRNA-mediated gene regulation in cholangiocyte defense). Thus, the experiments will define the molecular mechanisms by which C. parvum-cholangiocyte interactions trigger host epithelial defense, with an emphasis on the role of miRNA- mediated post-transcriptional regulation in TLR-associated defense, a NEW CONCEPT that may have important generalizability to both innate and adaptive immunity in health and disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Midwest DDRCC Alliance Conference (Hosted by the Mayo Clinic DDRCC)
  • 批准号:
    10675868
  • 项目类别:
  • 资助金额:
    $2.2万
  • 财政年份:
    2023
  • 负责人:
    Nicholas F. LaRusso
  • 依托单位:
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies
The Development of TGR5 Antagonists for the Treatment of Cholangiopathies
海外基金